Jul 24, 2025, 07:57

Innovative Surgery as the Cornerstone of Affordable Multi-Modal Interventions in Locally Advanced or Metastatic Cancer

This Research & Innovation Action under Horizon Europe will validate surgery-centred, multi-modal treatment strategies—including minimally invasive techniques combined with medical devices or adjunct therapies—in academic investigator-initiated clinical trials for patients with locally advanced or metastatic solid tumours. Projects must demonstrate clinical effectiveness, patient-reported outcomes, quality of life improvements and cost-effectiveness across diverse European healthcare settings, with open-science data sharing via UNCAN.eu.

Eligibility Criteria:

Consortium of ≥3 independent legal entities from Horizon Europe Member States or Associated Countries
Academic lead partners capable of sponsoring and running investigator-initiated clinical trials
Inclusion of multidisciplinary stakeholders (surgeons, clinicians, patients/caregivers, SMEs, health economists, SSH experts)
Commitment to sex-/gender-disaggregated data and socio-economic/cultural diversity in trial design
Plans for cost-effectiveness analysis and metadata registration in the European Health Data Space

Funding Details:

Action Type: HORIZON-RIA (Research & Innovation Action)
Total Budget: €31 000 000
Indicative Grants: 4 grants of €7 000 000–€10 000 000 each
Model: Single-stage, budget-based action grant

Deadline:

Submit via the EU Funding & Tenders Portal by 16 September 2025, 17:00 Brussels time.

Where to Apply & More Info:

EU Funding & Tenders Portal – search HORIZON-MISS-2025-02-CANCER-03
Horizon Europe Work Programme 2025, “Supporting the implementation of the Cancer Mission”
Horizon Europe Programme Guide and Online Manual on the Portal

Cancer Mission clinical trials cost-effectiveness Horizon Europe innovative surgery metastatic cancer multi-modal therapy Multidisciplinary RIA UNCAN.eu

Marking One Year of Progress in IDH-Mutant Glioma Treatment - Servier Pharmaceuticals

James Whale Dies at 74: The Radio Icon’s Long Fight Against Kidney Cancer

A Pivotal Day for Geron

Top GU Immunotherapy Trials to Watch at ESMO 2025

Julie Gralow Received the 2025 NCG Lifetime Achievement Award in Oncology